Tubular breast cancer experience at Washington University: a review of the literature.
Our objective was to review the presentation and management of patients with tubular breast cancer treated at Barnes-Jewish Hospital and compare our findings with the available literature. Of 3908 cases of breast cancer treated at our institution between 1986 and 1995, the incidence of tubular breast cancer at Barnes-Jewish Hospital was 1.25%. We reviewed the breast cancer risks, initial presentation, treatment, and outcome of 39 women with 40 tubular breast cancers and compared our series with others in the literature. The mean patient age was 67 years, which is older than most other series. Twenty-nine of the 39 cancers (74%) were detected by screening mammography; the remainder presented with a palpable breast mass. The mean tumor size was 8 mm (range, 1-60 mm). Twenty-three of 25 tumors were ER+ (92%) and none had axillary nodal involvement. Bilateral breast cancer developed in 3 patients (8%). An additional 500 cases of tubular breast cancer have been described in the literature. When the component of the invasive tumor is > 75% tubular carcinoma, most patients present with early-stage disease that is ER+ in 47 of 56 tumors (84%). The natural history is indolent and metastases are rare. Bilateral breast cancer developed in 58 of the 540 cases (11%), 4 of which were tubular carcinomas. Local recurrences developed in 9 of 29 patients (31%) treated by excision alone. The role of tamoxifen has not been determined. Given the available data, the initial surgical staging and management of tubular carcinoma should be identical to other invasive histologies.
Holland
D W
DW
Department of Medicine, Washington University, St. Louis, MO, USA.
Boucher
L D
LD
Mortimer
J E
JE
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006785:Hospitals, University; D006801:Humans; D008327:Mammography; D008403:Mass Screening / Q000379:methods; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D008923:Missouri / Q000453:epidemiology; D009367:Neoplasm Staging; D010173:Palpation; D018714:Radiotherapy, Adjuvant; D011960:Receptors, Estrogen / Q000032:analysis; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011960:Receptors, Estrogen